FDA and Industry Devise "Least Burdensome" Device Approval Strategy
This article was originally published in The Silver Sheet
Executive SummaryIMPLEMENTATION OF THE "LEAST BURDENSOME" CONCEPT prescribed by Sec. 205 of the FDA Modernization Act will affect "virtually all" of FDA's medical device premarket approval activities, agency officials pledge. Industry hopes the FDAMA provisions, which require the agency to consider the "least burdensome" means for making PMA and 510(k) determinations, will foster quicker product development times. FDA and industry recently released a least burdensome "concept and principles" document that recommends exploring alternatives to randomized, controlled trials to support product approvals. A least burdensome approach is expected to foster greater interaction between product sponsors and FDA reviewers and increased use of new communication tools provided under FDAMA. WARNING LETTERS: FDA requests outside certification from Somnus Medical for corrective actions to address QS reg deficiencies; Datascope VasoSeal ES complication rate claims are "false and misleading," agency says
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.